We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sphere Fluidics Announces Enhanced Cyto-Mine Capability and Performance

Sphere Fluidics Announces Enhanced Cyto-Mine Capability and Performance content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced it has enhanced the capability and performance of its Cyto-Mine® System. The simplified design offers improved functionality to help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run.

Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. It is now faster and easier to manufacture, commission and service as a result of a simplified internal design. The new electronics design improves system performance, reliability, and stability, while the updated software features help to provide a better user experience, reduce user-instrument interaction, and allow for more robust data analysis. The enhanced capability and performance for the instrument, enables users to access more functionality and the improved software offers a more advanced and reliable system to help further simplify antibody discovery, cell line development, cell therapy, and synthetic biology workflows.

Dr. Marian Rehak, VP of Research and Development at Sphere Fluidics, said: “The new design is the culmination of 18 months' hard work by our R&D team. Due to the deployment of these latest improvements, researchers are now able to perform even faster selective screening of single cells to find rare lead candidates. Although, principally designed for antibody discovery and cell line development, the platform is very flexible and has now been demonstrated to be useful in a wide variety of application areas.”

Rob Treanor, Operations Director at Sphere Fluidics, said: “The new Cyto-Mine design not only unlocks increased functionality for scientists but is also faster to manufacture, commission, and service. A new user can learn how to run our user-friendly software within a single working day. We are helping our users to simplify their workflows with the added operational benefit of enhancing our service and support capacity.”